An Oxford systematic review of 9,341 adults across 37 studies found people who stopped Semaglutide or Tirzepatide regained about 0.8 kg, or 1.8 pounds, a month.
At that pace, patients would return to their starting weight in roughly 18 months; lead investigator Sam West said users who lose about 15 kg regain nearly 10 kg within the first year.
The review found regain after stopping GLP-1 drugs ran about 0.3 kg a month faster than after behavioral weight-loss programs, suggesting a stronger rebound effect once the medicines end.
Cost sharpens the issue: Wegovy and Zepbound typically run about $1,000 to $1,300 a month without insurance, reinforcing the view that these drugs manage obesity as a long-term condition rather than cure it.
A separate Cleveland Clinic study of 7,938 patients found some real-world users regained less because they restarted treatment or switched therapies, but stopping without an alternative still usually led to weight gain.
Your body is hardwired to regain lost weight. Can new medical procedures permanently lower this biological 'set point'?
GLP-1 drugs can strip away muscle with fat. Are we close to a new treatment that targets only fat loss?
Weight Regain After Stopping GLP-1 Medications: Key Findings, Patient Impact, and Future Directions
Overview
Stopping GLP-1 receptor agonist medications leads to a rapid regain of lost weight and a reversal of health benefits, as many patients discontinue treatment within the first year. Recent findings show that patients typically regain nearly 5 kg in the first year after stopping, and weight often returns to baseline within 1.7 years. This quick rebound highlights the chronic nature of obesity and the need for ongoing management beyond medication. High discontinuation rates, especially among older adults with diabetes, make it crucial to combine GLP-1 therapy with lasting lifestyle changes for better long-term results.